Literature DB >> 30198974

18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma.

Ismaheel O Lawal1, Alfred O Ankrah1,2, Gbenga O Popoola3, Nozipho E Nyakale4, Tebatso G Boshomane1, Florette Reyneke1, Thabo Lengana1, Mariza Vorster1, Mike M Sathekge1.   

Abstract

OBJECTIVES: Baseline metabolic metrics on fluorine-18-fluorodeoxyglucose PET (F-FDG PET) have prognostic value in Hodgkin lymphoma. International Prognostic Score (IPS) is used in the risk stratification of Hodgkin lymphoma. We compared the metabolic indices in HIV-infected and the IPS in HIV-infected and uninfected patients with Hodgkin lymphoma. PATIENTS AND METHODS: We retrospectively reviewed the data of HIV-infected and HIV-uninfected patients with classic Hodgkin lymphoma who had F-FDG PET for staging and compared the maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, and total lesion glycolysis between the two groups. We also compared the IPS and other prognostic indicators and correlated them with the metabolic indices in the two groups.
RESULTS: We studied 160 patients, which included 57 patients who were infected with HIV. The mean age was 33.84±11.88 years, with 38% (n=61) being female. The median cluster of differentiation 4 count and HIV viral load were 259 cells/mm and 4837.50 copies/ml, respectively. No significant difference in maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, and total lesion glycolysis between the two groups was found. Among the seven parameters of the IPS, only male sex (HIV-uninfected group higher, P=0.005) and serum albumin less than 4 g/dl were significantly different. The other parameters were not significantly different between the two groups. Other prognostic indicators including bulky disease, extranodal involvement, and the number of nodal groups involved were not significantly different between the two groups.
CONCLUSION: There was no significant difference in F-FDG metabolic parameters, IPS, and other risk indicators between HIV-infected and HIV-uninfected patients with Hodgkin lymphoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30198974     DOI: 10.1097/MNM.0000000000000905

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  Fluorodeoxyglucose Positron Emission Tomography integrated with computed tomography in carcinoma of the cervix: Its impact on accurate staging and the predictive role of its metabolic parameters.

Authors:  Ismaheel O Lawal; Thabo Lengana; Charl Janse van Rensburg; Florette Reyneke; Gbenga O Popoola; Alfred O Ankrah; Mike M Sathekge
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

2.  Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis.

Authors:  Ismaheel O Lawal; Kgomotso M G Mokoala; Matsontso Mathebula; Ingrid Moagi; Gbenga O Popoola; Nontando Moeketsi; Maphoshane Nchabeleng; Chris Hikuam; Jerrold J Ellner; Mark Hatherill; Bernard P Fourie; Mike M Sathekge
Journal:  Front Med (Lausanne)       Date:  2022-02-22

3.  The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Treatment Response and Survival in Paediatric and Adolescent Hodgkin Lymphoma.

Authors:  Janet Denise Reed; Andries Masenge; Ane Buchner; Fareed Omar; David Reynders; Mariza Vorster; Christophe Van de Wiele; Mike Sathekge
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

4.  The Use of 18F-FDG PET/CT Metabolic Parameters in Predicting Overall Survival in Patients Undergoing Restaging for Malignant Melanoma.

Authors:  Khanyisile N Hlongwa; Kgomotso M G Mokoala; Zvifadzo Matsena-Zingoni; Mariza Vorster; Mike M Sathekge
Journal:  Diagnostics (Basel)       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.